Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

durvalumab × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 223 Gastrointestinal 179 Genitourinary 65 Breast 57 Head & Neck 53 Gynecologic 40 Other solid neoplasm 23 Dermatologic 19 Lymphoid 14 Tumor-Agnostic 12 Sarcoma 12 CNS 7 Plasma cell 5 Endocrine 5 Other hematologic neoplasm 4 Myeloid 3 Other neoplasm 1 NET 1 Classical hematology 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 44 Everolimus 35 Magnetic Resonance Spectroscopy 20 Temozolomide 14 lanreotide 13 gallium Ga 68 dotatate 13 Octreotide 13 Nivolumab 11 Capecitabine 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 surufatinib 10 pembrolizumab 9 Sunitinib 9 Specimen Handling 9 cabozantinib 8 pasireotide 7 Positron Emission Tomography Computed Tomography 7 Lutetium-177 7 3-Iodobenzylguanidine 7 Somatostatin 6 Fluorodeoxyglucose F18 6 90Y-octreotide, DOTA-Tyr(3)- 6 copper dotatate CU-64 5 amino-acid, glucose, and electrolyte solution 5 Ipilimumab 5 Injections 5 Ga(III)-DOTATOC 5 Etoposide 5 Data Collection 5 Carboplatin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03095274 2025-01-09

DUNE

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

126 enrolled 18 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡